Singapore, April 14 -- Senhwa Biosciences, Inc., a Taiwan-based clinical-stage biopharmaceutical company, has announced the signing of a Memorandum of Understanding (MoU) with GEM YIELD BAHAMAS, an affiliate of the global investment firm Global Emerging Markets (GEM).

Under the agreement, GEM intends to provide up to NT$500 million in terms of strategic funding to support Senhwa's advancing pipeline, AI-enabled drug discovery initiatives, and global expansion strategy.

AI-enabled validation has demonstrated that Senhwa's lead candidates possess promising immunomodulatory potential under specific tumor microenvironment conditions. These findings support the company's "cold-to-hot tumour" strategy, positioning Senhwa to capture opportunit...